COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences

by Microdose

January 6, 2021

in Press Releases

Reading Time: 1 min read

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

London, UK, Jan. 06, 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in two investor conferences during the week of 11 January 2021.

Order Reliable Lasix Online

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing

WordPress Ads

No Result

View All Result

COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Microdose

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Follow us on social